Alexander C Flint1, Bonnie S Faigeles, Sean P Cullen, Hooman Kamel, Vivek A Rao, Rishi Gupta, Wade S Smith, Philip M Bath, Geoffrey A Donnan. 1. From the Department of Neuroscience, Kaiser Permanente, Redwood City, CA (A.C.F., B.S.F., S.P.C., V.A.R.); Department of Neurology and Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (H.K.); Departments of Neurology, Neurosurgery, and Radiology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA (R.G.); Department of Neurology, University of California San Francisco (W.S.S.); Stroke Trials Unit, University of Nottingham, Nottingham, United Kingdom (P.M.B.); and The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia (G.A.D.).
Abstract
BACKGROUND AND PURPOSE: In previous studies, the Totaled Health Risks in Vascular Events (THRIVE) score has shown broad utility, allowing prediction of clinical outcome, death, and risk of hemorrhage after tissue-type plasminogen activator (tPA) treatment, irrespective of the type of acute stroke therapy applied to the patient. METHODS: We used data from the Virtual International Stroke Trials Archive to further validate the THRIVE score in a large cohort of patients receiving tPA or no acute treatment, to confirm the relationship between THRIVE and hemorrhage after tPA, and to compare the THRIVE score with several other available outcome prediction scores. RESULTS: The THRIVE score strongly predicts clinical outcome (odds ratio, 0.55 for good outcome [95% CI, 0.53-0.57]; P<0.001), mortality (odds ratio, 1.57 [95% confidence interval, 1.50-1.64]; P<0.001), and risk of intracerebral hemorrhage after tPA (odds ratio, 1.34 [95% confidence interval, 1.22-1.46]; P<0.001). The relationship between THRIVE score and outcome is not influenced by the independent relationship of tPA administration and outcome. In receiver operator characteristic curve analysis, the THRIVE score was superior to several other available outcome prediction scores in the prediction of clinical outcome and mortality. CONCLUSIONS: The THRIVE score is a simple-to-use tool to predict clinical outcome, mortality, and risk of hemorrhage after thrombolysis in patients with ischemic stroke. Despite its simplicity, the THRIVE score performs better than several other outcome prediction tools. A free Web calculator for the THRIVE score is available at http://www.thrivescore.org.
BACKGROUND AND PURPOSE: In previous studies, the Totaled Health Risks in Vascular Events (THRIVE) score has shown broad utility, allowing prediction of clinical outcome, death, and risk of hemorrhage after tissue-type plasminogen activator (tPA) treatment, irrespective of the type of acute stroke therapy applied to the patient. METHODS: We used data from the Virtual International Stroke Trials Archive to further validate the THRIVE score in a large cohort of patients receiving tPA or no acute treatment, to confirm the relationship between THRIVE and hemorrhage after tPA, and to compare the THRIVE score with several other available outcome prediction scores. RESULTS: The THRIVE score strongly predicts clinical outcome (odds ratio, 0.55 for good outcome [95% CI, 0.53-0.57]; P<0.001), mortality (odds ratio, 1.57 [95% confidence interval, 1.50-1.64]; P<0.001), and risk of intracerebral hemorrhage after tPA (odds ratio, 1.34 [95% confidence interval, 1.22-1.46]; P<0.001). The relationship between THRIVE score and outcome is not influenced by the independent relationship of tPA administration and outcome. In receiver operator characteristic curve analysis, the THRIVE score was superior to several other available outcome prediction scores in the prediction of clinical outcome and mortality. CONCLUSIONS: The THRIVE score is a simple-to-use tool to predict clinical outcome, mortality, and risk of hemorrhage after thrombolysis in patients with ischemic stroke. Despite its simplicity, the THRIVE score performs better than several other outcome prediction tools. A free Web calculator for the THRIVE score is available at http://www.thrivescore.org.
Authors: Thoralf Thamm; Jia Guo; Jarrett Rosenberg; Tie Liang; Michael P Marks; Soren Christensen; Huy M Do; Stephanie M Kemp; Emma Adair; Irina Eyngorn; Michael Mlynash; Tudor G Jovin; Bart P Keogh; Hui J Chen; Maarten G Lansberg; Gregory W Albers; Greg Zaharchuk Journal: Stroke Date: 2019-10-17 Impact factor: 7.914
Authors: Alexander C Flint; Sean P Cullen; Vivek A Rao; Bonnie S Faigeles; Vitor M Pereira; Elad I Levy; Tudor G Jovin; David S Liebeskind; Raul G Nogueira; Reza Jahan; Jeffrey L Saver Journal: Int J Stroke Date: 2014-05-20 Impact factor: 5.266
Authors: Alexander C Flint; Bin Xiang; Rishi Gupta; Raul G Nogueira; Helmi L Lutsep; Tudor G Jovin; Gregory W Albers; David S Liebeskind; Nerses Sanossian; Wade S Smith Journal: Stroke Date: 2013-09-26 Impact factor: 7.914
Authors: Sunil A Sheth; Nerses Sanossian; Qing Hao; Sidney Starkman; Latisha K Ali; Doojin Kim; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Gary R Duckwiler; Jeffrey L Saver; Fernando Vinuela; David S Liebeskind Journal: J Neurointerv Surg Date: 2014-11-06 Impact factor: 5.836
Authors: Mei-Ling Sharon Tai; Khean Jin Goh; Khairul Azmi Abdul Kadir; Mohd Idzwan Zakaria; Jun Fai Yap; Kay Sin Tan Journal: Singapore Med J Date: 2018-11-29 Impact factor: 1.858
Authors: Oliver Bracko; Valentina Di Pietro; Giacomo Lazzarino; Angela M Amorini; Barbara Tavazzi; Judith Artmann; Eric C Wong; Richard B Buxton; Michael Weller; Andreas R Luft; Susanne Wegener Journal: J Cereb Blood Flow Metab Date: 2014-06-18 Impact factor: 6.200